These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35078455)

  • 21. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
    Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
    Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
    Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
    Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
    Aihara T; Kim Y; Takatsuka Y
    Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
    Shimura Y; Suga Y; Itai S; Iwamoto H; Takezawa Y; Yaegashi H; Izumi K; Shimada T; Sai Y; Matsushita R; Mizokami A
    Anticancer Res; 2020 Aug; 40(8):4291-4297. PubMed ID: 32727756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
    Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
    J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
    Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.
    Andre F; Broglio K; Pusztai L; Berrada N; Mackey JR; Nabholtz JM; Chan S; Hortobagyi GN
    Oncologist; 2010; 15(5):476-83. PubMed ID: 20421265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
    Stemmler HJ; Gutschow K; Sommer H; Malekmohammadi M; Kentenich CH; Forstpointner R; Geuenich S; Bischoff J; Hiddemann W; Heinemann V
    Ann Oncol; 2001 Oct; 12(10):1393-8. PubMed ID: 11762809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study.
    Sawaki M; Ito Y; Hashimoto D; Mizunuma N; Takahashi S; Horikoshi N; Tada K; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
    Tumori; 2004; 90(1):36-9. PubMed ID: 15143969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
    Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
    Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
    Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.
    Ko YH; Lee MA; Hong YS; Lee KS; Park HJ; Yoo IeR; Kim YS; Kim YK; Jo KH; Wang YP; Lee KY; Kang JH
    Korean J Intern Med; 2007 Sep; 22(3):178-85. PubMed ID: 17939335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.